| First Author | Zhou Y | Year | 2020 |
| Journal | Immunity | Volume | 52 |
| Issue | 2 | Pages | 357-373.e9 |
| PubMed ID | 32049051 | Mgi Jnum | J:288823 |
| Mgi Id | MGI:6431939 | Doi | 10.1016/j.immuni.2020.01.014 |
| Citation | Zhou Y, et al. (2020) Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity 52(2):357-373.e9 |
| abstractText | Clearance of apoptotic cells by macrophages prevents excessive inflammation and supports immune tolerance. Here, we examined the effect of blocking apoptotic cell clearance on anti-tumor immune response. We generated an antibody that selectively inhibited efferocytosis by phagocytic receptor MerTK. Blockade of MerTK resulted in accumulation of apoptotic cells within tumors and triggered a type I interferon response. Treatment of tumor-bearing mice with anti-MerTK antibody stimulated T cell activation and synergized with anti-PD-1 or anti-PD-L1 therapy. The anti-tumor effect induced by anti-MerTK treatment was lost in Sting(gt/gt) mice, but not in Cgas(-/-) mice. Abolishing cGAMP production in Cgas(-/-) tumor cells, depletion of extracellular ATP, or inactivation of the ATP-gated P2X7R channel also compromised the effects of MerTK blockade. Mechanistically, extracellular ATP acted via P2X7R to enhance the transport of extracellular cGAMP into macrophages and subsequent STING activation. Thus, MerTK blockade increases tumor immunogenicity and potentiates anti-tumor immunity, which has implications for cancer immunotherapy. |
